Tetraphase Pharmaceuticals Announces Presentation of Data at IDWEEK on the Activity of Eravacycline Against Multidrug-Resistant Bacteria

- Data Highlight In Vitro Activity of Eravacycline Against Pathogens Considered Among the Most Serious Public Health Threats -

WATERTOWN, Mass.--()--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that researchers will present a poster at IDWeek 2014 showing the preclinical activity of eravacycline, a novel tetracycline in late-stage clinical development, against several Gram-negative pathogens found in New York City—a city particularly plagued by multidrug-resistant (MDR) bacteria. The researchers concluded that eravacycline, which is presently being studied in Phase 3 trials for complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), demonstrated excellent in vitro activity against Gram-negative MDR strains of E. coli, Klebsiella pnuemoniae, Enterobacter spp., and Acinetobacter baumannii. IDWeek takes place from October 8 – 12 in Philadelphia at The Pennsylvania Convention Center.

“We are very encouraged by these data as they speak specifically to eravacycline’s potential against some of the most virulent, Gram-negative multidrug-resistant bacteria that have plagued hospitals and emerged as a serious public health threat,” said Guy Macdonald, President and CEO of Tetraphase. “Coming on the heels of President Obama’s recent executive order on antibiotic resistance, and his call for ‘next-generation antibiotics,’ we are very pleased to be part of the effort to combat this growing public health threat. We look forward to continuing to progress eravacycline through Phase 3 clinical trials with the goal of offering this important new medicine to patients.”

Researchers will present:

  • “Activity of Eravacycline Against Enterobacteriaceae and Acinetobacter Baumannii from New York City” [Poster 253] on Thursday, October 9, 2014, 12:30 p.m. – 2:00 p.m. ET. Poster Abstract Session: “Antimicrobial Resistance: Novel Agents and Approaches to Gram-negative Infections” (IDExpo Hall BC)

In addition to the eravacycline poster, Tetraphase-sponsored research is highlighted via a second poster presentation related to Gram-negative MDR bacteria:

  • “Predictors of Hospital Mortality among Septic ICU Patients with Acinetobacter spp. bacteremia: A Cohort Study.” [Poster 718] on Friday, October 10, 2014, 12:30 p.m. – 2:00 p.m. ET. Poster Abstract Session: “Bacteremia: Gram-Negative Bacteremia” (IDExpo Hall BC)

About Tetraphase Pharmaceuticals, Inc.

Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC). Tetraphase's lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic in the IGNITE program (Investigating Gram-negative Infections Treated with Eravacycline). Under this program, two Phase 3 clinical trials are ongoing: IGNITE 1 for the indication of complicated intra-abdominal infections (cIAI) and IGNITE 2 for complicated urinary tract infections (cUTI). Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform; in addition to eravacycline, Tetraphase has generated multiple preclinical antibiotic candidates that are currently being evaluated for clinical suitability.

Forward-Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward- looking statements as a result of various important factors, including: whether our cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in preclinical studies such as the results referenced in this release will be indicative of results obtained in clinical trials; whether eravacycline will advance through the clinical trial process on a timely basis or at all; whether submissions will be made and approvals will be received from the United States Food and Drug Administration or equivalent foreign regulatory agencies on a timely basis or at all; whether, if eravacycline obtains approval, it will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of our most recent Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 12, 2014. In addition, the forward-looking statements included in this press release represent our views as of October 8, 2014. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

Contacts

Investors:
Tetraphase Pharmaceuticals
Teri Dahlman, 617-600-7040
tdahlman@tphase.com
or
Argot Partners
Susan Kim, 212-600-1902
susan@argotpartners.com
or
Media:
Sam Brown Inc.
Mike Beyer, 773-463-4211
beyer@sambrown.com

Contacts

Investors:
Tetraphase Pharmaceuticals
Teri Dahlman, 617-600-7040
tdahlman@tphase.com
or
Argot Partners
Susan Kim, 212-600-1902
susan@argotpartners.com
or
Media:
Sam Brown Inc.
Mike Beyer, 773-463-4211
beyer@sambrown.com